Topic: intellectual property
The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.
Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.
The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.
China is a big area of opportunity for biotech with a sizable and growing chunk of the population succumbing to chronic, middle-class diseases.
Four of Genentech’s former U.S. researchers are accused of passing information to a foreign rival developing biosimilars of its top drugs.
There’s no one-size-fits-all solution when it comes to academic partnerships, but successful ones have one thing in common: communication.
Another scientist who previously worked for GSK has admitted conspiring to steal trade secrets and pass them on to a Chinese rival.
In a blow to the University of California, a federal appeals court upheld CRISPR patents held by the Broad Institute.
Dicerna and Alnylam are settling a yearslong spat over trade secrets relating to gene-silencing technology.
Novartis is paying $31 million upfront for gevokizumab, a price that reflects the battering its prospects took as a development program unraveled.